YI
111, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · CN
$3.51
+5.26%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 11.3B | 12.2B | 14.4B | 14.9B | 13.5B |
| Cost of Revenue | 10.7B | 11.5B | 13.6B | 14.1B | 12.7B |
| Gross Profit | 652.0M | 703.7M | 829.2M | 849.0M | 840.0M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 384.4M | 655.0M | 384.8M | 672.6M | 663.5M |
| General & Admin Expense | 60.3M | 58.7M | 70.9M | 224.2M | 205.6M |
| Selling & Marketing Expense | 324.1M | 596.2M | 313.9M | 448.4M | 457.9M |
| Other Expenses | 294.4M | 58.7M | 442.3M | 526.5M | 547.5M |
| Total Operating Expenses | 678.8M | 713.7M | 827.1M | 1.2B | 1.2B |
| Cost and Expenses | 11.4B | 12.2B | 14.4B | 15.3B | 13.9B |
| Operating Income (EBIT) | (26.8M) | (10.0M) | 2.1M | (350.1M) | (371.0M) |
| Non-Operating | |||||
| Interest Income | 3.4M | 3.8M | 7.0M | 8.8M | 8.1M |
| Interest Expense | 34.5M | 34.6M | 28.3M | 20.1M | 13.4M |
| Net Interest Income | (31.2M) | (30.8M) | (21.3M) | (11.3M) | (5.3M) |
| Other Non-Op Income/Expense | (15.1M) | (11.9M) | (22.8M) | (3.1M) | (5.1M) |
| Non-Operating Income (excl Interest) | (15.2M) | — | (5.5M) | (17.1M) | (8.4M) |
| EBT (Pre-Tax Income) | (41.9M) | (21.9M) | (20.7M) | (353.2M) | (376.1M) |
| Income Tax Expense | (3.0K) | 12.6K | 96.0K | 251.0K | — |
| Bottom Line | |||||
| Net Income | (75.4M) | (16.8M) | (64.7M) | (392.7M) | (416.9M) |
| Earnings from Cont. Ops | (41.9M) | (21.9M) | (20.8M) | (353.4M) | (376.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (85.6M) | (64.6M) | (64.7M) | (392.7M) | (416.9M) |
| Per Share | |||||
| Basic EPS | ($9.76) | ($7.42) | ($7.52) | ($46.58) | ($50.04) |
| Diluted EPS | ($9.76) | ($7.42) | ($7.52) | ($46.58) | ($50.04) |
| Revenue Per Share | $1,290.45 | $1,403.69 | $1,671.18 | $1,773.11 | $1,622.32 |
| Shares | |||||
| Basic Shares Outstanding | 8.8M | 8.7M | 8.6M | 8.4M | 8.3M |
| Diluted Shares Outstanding | 8.8M | 8.7M | 8.6M | 8.4M | 8.3M |
| Profitability Metrics | |||||
| EBITDA | (16.8M) | 1.8M | 24.6M | (311.3M) | (321.8M) |
| D&A | — | 11.8M | 17.0M | 21.8M | 40.8M |
| EBIT | (16.8M) | (10.0M) | 7.7M | (333.0M) | (362.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026